Beyond Weight Loss: Lancet Psychiatry Study of 100,000 People Links Semaglutide to 44% Lower Depression Risk

A massive Swedish national cohort study published in The Lancet Psychiatry reveals that semaglutide is associated with dramatic reductions in depression, anxiety, and substance use disorders — shifting the conversation about GLP-1 drugs from body weight to brain health.

Presented By Our Partners

When Ozempic and Wegovy became cultural phenomena for their dramatic weight loss effects, most researchers treated psychiatric risk as a liability to manage, not a benefit to investigate. The FDA spent much of 2023 scrutinizing early signals that GLP-1 receptor agonists might be associated with suicidal ideation. Clinical trial teams added psychiatric safety monitoring as a precaution. The assumption was that these were metabolic drugs with a psychiatric footnote to watch.

A sweeping new study published in April 2026 in The Lancet Psychiatry has inverted that assumption entirely. Analyzing national health register data from Sweden covering more than 100,000 individuals, researchers at the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia found that periods of semaglutide use were associated with a 42% reduction in psychiatric hospital care and psychiatric sick leave, a 44% lower risk of worsening depression, a 38% lower risk of anxiety disorders, and a 47% reduction in hospital care and work absence tied to substance use disorders.

These are not incremental associations. They are findings that, if replicated in randomized trials, could fundamentally reshape how psychiatry thinks about treatment-resistant depression, anxiety, and addiction — and how medicine thinks about GLP-1 drugs.

The Study: 100,000 People, a Decade of National Data

The research team, led by investigators with affiliations at the University of Eastern Finland and Karolinska Institutet, drew on Sweden’s national electronic health registers, one of the most comprehensive longitudinal health databases in the world. The study cohort included people with a formal diagnosis of depression or anxiety disorder who had used any antidiabetic medication between 2009 and 2022. More than 20,000 individuals within the cohort had used GLP-1 receptor agonists.

The design used a within-person comparison: each participant’s psychiatric outcomes during periods of GLP-1 medication use were compared against the same person’s outcomes during periods when they were not using the medication. This approach is particularly powerful because it controls for all the stable personal characteristics, genetics, lifestyle factors, and baseline psychiatric severity, that might otherwise confound a between-person comparison. When you are your own control group, confounding is dramatically reduced.

The primary outcome was a composite measure of worsening mental illness: psychiatric hospitalization, sick leave for psychiatric reasons lasting more than 14 days, hospitalization due to self-harm, or death by suicide. Secondary outcomes broke out depression, anxiety, and substance use disorders separately.

The headline finding was unambiguous. During semaglutide use, the composite psychiatric worsening outcome dropped by 42% compared to periods without the drug. Liraglutide, another GLP-1 receptor agonist, was associated with an 18% reduction. Notably, the other agents in the class, exenatide and dulaglutide, showed no significant risk reduction. The psychiatric signal appears to be strongest with the newer, more potent GLP-1 drugs.

Why Would a Diabetes Drug Improve Mental Health?

The answer lies in neuroanatomy that the medical community is still mapping. GLP-1 receptors are not confined to the pancreas and gut. They are distributed throughout the brain, with particularly dense expression in regions that govern mood, reward, appetite, and emotional regulation, including the hypothalamus, the hippocampus, the cerebral cortex, and areas of the brainstem involved in the stress response.

Research published in Cellular and Molecular Neurobiology in early 2025 laid out the neuroinflammatory pathway in detail. Semaglutide appears to stimulate the production of anti-inflammatory cytokines within the brain, reducing neuroinflammation, which is increasingly recognized as a driver of both depression and anxiety. Neuroinflammation disrupts the delicate chemical signaling that regulates serotonin and dopamine, two of the most important neurotransmitters for mood stability and motivation.

There is also a tryptophan angle. In metabolic dysfunction and diabetes, low-grade systemic inflammation can accelerate the metabolism of tryptophan, the amino acid precursor to serotonin, along the kynurenine pathway rather than the serotonin pathway. The result is serotonin depletion. By reducing systemic and neuroinflammation, GLP-1 receptor agonists may restore more tryptophan toward serotonin synthesis, improving the neurochemical substrate for mood regulation.

Animal model studies have gone further, showing that GLP-1 receptor activation promotes neurogenesis in the hippocampus, the brain region most associated with memory and depressive symptoms, and enhances synaptic plasticity in mood-relevant circuits. The convergence of anti-inflammatory, serotonergic, dopaminergic, and neurogenic mechanisms may explain why semaglutide’s psychiatric signal is so broad: it appears to work on multiple pathways simultaneously.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The Substance Use Finding: Equally Striking

Perhaps the most underreported dimension of the Lancet Psychiatry data is the 47% reduction in substance use disorder outcomes during semaglutide use. This is consistent with a growing body of animal and small human studies showing that GLP-1 receptor agonists reduce cravings and impulsive reward-seeking behavior across a range of addictive substances, including alcohol, opioids, nicotine, and high-sugar, high-fat foods.

The mechanism here involves the mesolimbic dopamine system, the brain’s reward circuitry. GLP-1 receptors in the ventral tegmental area and nucleus accumbens modulate how strongly the brain responds to rewarding stimuli. In animal models, GLP-1 receptor activation blunts the dopamine surge associated with substance ingestion, reducing the reinforcing value of the addictive behavior. If this mechanism operates in humans at the scale suggested by the Swedish data, GLP-1 receptor agonists may represent a novel pharmacological approach to addiction that works through an entirely different pathway than current treatments like naltrexone or buprenorphine.

The clinical implications are staggering. More than 20 million Americans meet diagnostic criteria for a substance use disorder. Existing pharmacological treatments are underused and only modestly effective for many patients. A drug already widely prescribed and generally well-tolerated that also reduces substance use by nearly half during periods of use would represent a transformative tool for addiction medicine.

Nuance: Not All GLP-1 Drugs Are Equal

The Lancet Psychiatry findings are not a blanket endorsement for every drug in the GLP-1 class. The psychiatric signal was clearly strongest for semaglutide, which showed the 42% composite reduction, and meaningful but more modest for liraglutide at 18%. Exenatide and dulaglutide showed no statistically significant psychiatric benefit in this dataset.

This differentiation matters. Semaglutide is a longer-acting, more potent GLP-1 receptor agonist than older agents like exenatide. Its pharmacokinetics allow it to maintain more sustained receptor occupancy, which may translate to more consistent neurobiological effects. The dose also matters: the higher doses used for weight management in Wegovy (2.4 mg weekly) are substantially above the doses used for diabetes in Ozempic (0.5 to 2 mg weekly), and the psychiatric data from the Swedish study did not fully disaggregate by indication and dose.

The study’s observational design also carries inherent limitations. Sweden’s national registers are among the world’s best health datasets, and the within-person design addresses many confounders, but it cannot rule out that people who remain on semaglutide are, by definition, healthier and more adherent patients than those who discontinued, a form of survival bias. Randomized controlled trials, several of which are now underway specifically examining psychiatric outcomes in semaglutide users, will be needed to establish causation.

An earlier, smaller randomized clinical trial published in 2026 in Journal of Psychiatric Research did provide randomized evidence: semaglutide improved cognitive dysfunction in patients with major depressive disorder compared to placebo, suggesting the neurobiological effects are real and not purely observational artifact.

Reversing the FDA Warning Narrative

In 2023, the FDA announced it would investigate whether GLP-1 receptor agonists were associated with increased suicidal thoughts and self-harm, following a small number of reports. That investigation introduced a cloud of psychiatric uncertainty over the drug class. The Lancet Psychiatry study, with its composite outcome that explicitly includes hospitalization for self-harm and death by suicide, points in the opposite direction. During semaglutide use, suicidal behavior was reduced, not elevated.

The researchers were careful in their language. This is a large observational study, and the findings deserve replication and scrutiny. But the scale of the data, the national scope of Sweden’s registers, the within-person design, and the consistency of findings across multiple psychiatric outcomes all add credibility to the signal. The experts at the Science Media Centre who reviewed the study on publication noted that the research methodology was sound and that the findings were biologically plausible given what is now known about GLP-1 receptor distribution in the brain.

This does not close the book on the FDA’s earlier concerns, but it substantially shifts the weight of evidence toward psychiatric benefit rather than psychiatric risk.

The Metabolic and Mental Health Connection: A Systems Lens

The Lancet Psychiatry findings are perhaps most meaningful when viewed through the lens of metabolic health as a foundation for brain health. The separation between metabolic medicine and psychiatric medicine has always been conceptually convenient but biologically artificial. Insulin resistance, chronic inflammation, gut microbiome dysbiosis, and mitochondrial dysfunction all have neuropsychiatric consequences, contributing to mood disorders, cognitive decline, and addiction vulnerability.

Semaglutide works upstream. By improving insulin sensitivity, reducing systemic inflammation, modulating gut hormone signaling, and acting directly on brain GLP-1 receptors, it intervenes in multiple root causes simultaneously. The 44% lower depression risk and 38% lower anxiety risk in the Swedish cohort may not be the drug’s primary action. They may be downstream consequences of correcting metabolic dysfunction that was silently eroding brain chemistry all along.

This perspective aligns with the emerging field of metabolic psychiatry, which argues that conditions like treatment-resistant depression and bipolar disorder have strong metabolic underpinnings that are underaddressed by the current psychiatry toolkit. If GLP-1 receptor agonists prove effective in randomized trials for psychiatric conditions, they would represent the first pharmacological bridge between metabolic medicine and psychiatric medicine in mainstream clinical practice.

What the Research Pipeline Looks Like Now

The scientific community is not waiting. Multiple large randomized trials are now specifically examining whether semaglutide and related GLP-1 receptor agonists can be used intentionally for psychiatric indications. Novo Nordisk, the maker of Ozempic and Wegovy, has funded research into semaglutide’s effects on substance use disorders. Academic research groups at institutions including Harvard, Johns Hopkins, and the Karolinska Institutet are actively investigating the neurobiological mechanisms using neuroimaging.

A 2025 meta-analysis published in The American Journal of Geriatric Psychiatry reviewed multiple GLP-1 receptor agonist studies and found consistent antidepressant effects across trials, though most individual studies were small. The Swedish cohort data now provides the largest single piece of real-world evidence supporting that meta-analytic signal.

There is also emerging interest in whether the psychiatric benefits of GLP-1 drugs are relevant for populations without diabetes or obesity. Most of the existing evidence comes from metabolically compromised patients. Whether the neurobiological effects are meaningful in people with normal metabolic function remains an open and important question for the field.

What This Means For You

If you are taking semaglutide or liraglutide for diabetes or weight management, this research provides reassurance. The largest real-world study to date, using rigorous within-person methodology and a decade of national data, found that psychiatric risk does not increase during GLP-1 use and in fact appears to decrease substantially for depression, anxiety, and substance use. This does not mean these medications are psychiatric drugs, and they should not be sought primarily for that purpose outside of clinical guidance, but it is meaningful contextual reassurance.

If you are a clinician managing patients on GLP-1 receptor agonists who also carry a psychiatric diagnosis, this research warrants attention. The findings suggest that semaglutide and liraglutide may be preferentially appropriate choices among antidiabetic and weight management options for patients with comorbid depression or anxiety, pending randomized trial confirmation.

If you are interested in the broader science of brain health and metabolic health, this study is a compelling reminder that these are not separate systems. The gut, the pancreas, the immune system, and the brain are in constant dialogue. Interventions that restore metabolic balance, whether through nutrition, movement, sleep, or targeted pharmacology, have the potential to reverberate all the way into mental health outcomes. The semaglutide psychiatric story is still being written, but the first 100,000 chapters are pointing in a striking direction.

References: Gustafsson et al., “Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study,” The Lancet Psychiatry, April 2026. Karolinska Institutet / University of Eastern Finland / Griffith University. Additional mechanistic research from Cellular and Molecular Neurobiology (2025), The American Journal of Geriatric Psychiatry meta-analysis (2025), and Journal of Psychiatric Research semaglutide RCT (2026).

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.